- Home
- ABEO vs ARDC Comparison
ABEO vs ARDC Comparison
Compare ABEO & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | ARDC |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 291.4M |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ABEO | ARDC |
|---|---|---|
| Price | $5.49 | $12.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 144.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $11.60 |
| 52 Week High | $7.54 | $15.03 |
Technical Indicators
Market Signals| Indicator | ABEO | ARDC |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 51.81 |
| Support Level | $5.24 | $12.04 |
| Resistance Level | $5.54 | $13.03 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 35.50 | 31.82 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-end, diversified, management investment company. The Fund's investment objective is to seek an attractive risk adjusted level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of (i) senior secured loans, (ii) corporate bonds, (iii) other fixed-income instruments, and (iv) securities issued by entities commonly referred to as collateralized loan obligations and other asset-backed securities.